| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/21/2005 | US6908732 Compounds and methods for regulating cell differentiation |
| 06/21/2005 | US6908631 Administering to individual in need of nicotine replacement therapy therapeutically effective amount of nicotine and methoxsalen, to enhance effectiveness |
| 06/21/2005 | US6908630 For therapy of inflammation, psoriasis |
| 06/21/2005 | US6908625 Cosmetic material containing triple- encapsulated retinol |
| 06/21/2005 | US6908623 Compositions and methods for enhancing receptor-mediated cellular internalization |
| 06/21/2005 | US6908622 Optimized dosing for drug coated stents |
| 06/21/2005 | US6908612 Virus coat protein/receptor chimeras and methods of use |
| 06/21/2005 | US6908611 Combination therapies using vitamin B12 and interferon for treatment of viral, proliferative and inflammatory diseases |
| 06/21/2005 | US6908610 Stable granulocyte colony stimulating factor formulation containing one or more of lysine, histidine, arginine, aspartic acid, glutamic acid, threonine and asparagine; one or more hydrophobic amino acids; and methionine |
| 06/21/2005 | US6908609 Removing fluid from the intestinal tract of a host by directly delivering an effective amount of water-absorbent polymer to the intestinal tract |
| 06/21/2005 | CA2382387C Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure |
| 06/21/2005 | CA2359541C Anticonvulsant derivatives useful in treating cluster headaches |
| 06/21/2005 | CA2309474C New 4-arylpiperidine derivatives for the treatment of pruritus |
| 06/21/2005 | CA2309473C New 4-arylpiperidine derivatives for the treatment of pruritus |
| 06/21/2005 | CA2294788C Therapeutical system for transdermal delivery of levonorgestrel |
| 06/21/2005 | CA2286299C Process for improving glucose metabolism, satiety, and nutrient absorption in companion animals |
| 06/21/2005 | CA2250372C 6-phenylpyridyl-2-amine derivatives |
| 06/21/2005 | CA2231143C Farnesyl transferase inhibiting 2-quinolone derivatives |
| 06/21/2005 | CA2213339C Method of treating adenosine depletion |
| 06/21/2005 | CA2180010C 7-¬carboxyalkyl or alkenyl|-6-¬alkyl or alkenyl| 3-oxo-2,4-dioxobicyclo-¬3.2.1| octane and derivatives thereof |
| 06/21/2005 | CA2161970C Method for the treatment of neoplastic disease utilizing tiazofurin and ribavirin |
| 06/21/2005 | CA2152403C Use of prostane derivatives of formulae i and ii for the production of a medicament for the treatment of chronic polyarthritis |
| 06/21/2005 | CA2150576C Injectable taxane derivatives based compositions |
| 06/21/2005 | CA2125579C Ulcer prevention treatment composition and method |
| 06/21/2005 | CA2108068C Carbamates of rapamycin |
| 06/21/2005 | CA2066304C Pharmaceutical composition for the treatment of autoimmune diseases |
| 06/19/2005 | CA2491278A1 Highly branched soluble glucose polymers |
| 06/17/2005 | CA2479432A1 Thiazole derivatives |
| 06/17/2005 | CA2453687A1 Therapeutic composition containing at least diflomotecan and capecitabin e |
| 06/16/2005 | WO2005054809A2 Irciniastatins a and b |
| 06/16/2005 | WO2005054496A1 Method of examining cell kinetics |
| 06/16/2005 | WO2005054473A1 GENETICALLY MODIFIED PLANTS COMPRISING SARS-CoV VIRAL NUCLEOTIDE SEQUENCES AND METHODS OF USE THEREOF FOR IMMUNIZATION AGAINST SARS |
| 06/16/2005 | WO2005054440A2 A biomimetic composition reinforced by a polyelectrolytic complex of hyaluronic acid and chitosan |
| 06/16/2005 | WO2005054437A2 Compositions and methods for ex vivo preservation of blood vessels for vascular grafts using inhibitor of type i and/or type ii phosphodiesterases |
| 06/16/2005 | WO2005054436A2 Compositions and methods for preservation of vascular grafts |
| 06/16/2005 | WO2005054432A2 Gene transfer for regulating smooth muscle tone |
| 06/16/2005 | WO2005054430A2 Hepatitis c virus inhibitors |
| 06/16/2005 | WO2005054428A2 Method for inhibiting cancer cells |
| 06/16/2005 | WO2005054299A1 A kind of polysaccharide, its preparation method and use |
| 06/16/2005 | WO2005054264A2 Glycomimetic antagonists for both e- and p-selectins |
| 06/16/2005 | WO2005054259A1 Phosphinic acid derivatives |
| 06/16/2005 | WO2005054258A2 New class of gamma delta t cells activators and use thereof |
| 06/16/2005 | WO2005054252A1 Crystal of hydrochloride of sulfoxide derivative |
| 06/16/2005 | WO2005054251A1 New cartharidic amine, demethyl cartharidic amine derivatives and their medicinal use |
| 06/16/2005 | WO2005054250A1 Tricyclacetalactonin, Preparation and Use there of |
| 06/16/2005 | WO2005054249A1 Novel compounds |
| 06/16/2005 | WO2005054247A1 Diazaindole-dicarbonyl-piperazinyl antiviral agents |
| 06/16/2005 | WO2005054244A2 Azabicyclooctene and other tetrahydropyridine derivatives with a new side-chain |
| 06/16/2005 | WO2005054240A1 Polymorphs of 1-cyclopropyl-7-([s,s]-2,8-diazadicyclo[4.3.0]non-8-yl)-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinoline carboxylic acid hydrochloride and methods for the preparation thereof |
| 06/16/2005 | WO2005054239A1 2-aminopyrimidine derivatives |
| 06/16/2005 | WO2005054238A1 1h-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases |
| 06/16/2005 | WO2005054237A1 1h-imidazoquinoline derivatives as protein kinase inhibitors |
| 06/16/2005 | WO2005054233A1 Benzoyl amino pyridil carboxylic acid derivatives as gluokinase activators |
| 06/16/2005 | WO2005054232A1 1-acetic acid-indole, -indazole and-benzimidazole derivatives usful for the treatment of respiratory disorders |
| 06/16/2005 | WO2005054231A1 Pyrazolyl and imidazolyl pyrimidines |
| 06/16/2005 | WO2005054225A1 Antidiabetic compounds comprising benzofuran and benzothiophene derivatives |
| 06/16/2005 | WO2005054224A2 Derivatives of dihydronepetalactone and method for preparation |
| 06/16/2005 | WO2005054217A1 Developments in biologically active methylene blue derivatives (2) |
| 06/16/2005 | WO2005054216A1 Novel anticancer agent “sulcoxin” |
| 06/16/2005 | WO2005054215A1 5-(benz- (z) -ylidene) -thiazolidin-4-one derivatives as immunosuppressant agents |
| 06/16/2005 | WO2005054213A1 Isoxazole derivative having agonistic activity against peroxisome proliferator-activated receptor |
| 06/16/2005 | WO2005054203A1 Quinoline derivatives substituted by aliphatic amino groups, the preparation and the pharmaceutical use thereof |
| 06/16/2005 | WO2005054199A1 Tubulin inhibitors |
| 06/16/2005 | WO2005054198A2 Therapeutics use of pyridinium compounds to modulate naadp activity |
| 06/16/2005 | WO2005054190A1 3-aminopyrrolidone derivatives |
| 06/16/2005 | WO2005054183A2 Quinolinone based protein kinase inhibitors |
| 06/16/2005 | WO2005054178A1 Cyclopentyl derivatives |
| 06/16/2005 | WO2005054177A1 Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides and use as renin inhibitors |
| 06/16/2005 | WO2005053796A1 Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists |
| 06/16/2005 | WO2005053747A1 Composition containing peg for perfusion of an active agent in particular paracetamol |
| 06/16/2005 | WO2005053746A1 Improved parasiticide composition |
| 06/16/2005 | WO2005053741A1 Medicine containing genetically modified antibody against chemokine receptor ccr4 |
| 06/16/2005 | WO2005053739A2 Combination therapy |
| 06/16/2005 | WO2005053735A1 Method of removing transition metals, especially from metathesis reaction products |
| 06/16/2005 | WO2005053724A1 Compositions and method for treatment of steroid/nuclear receptor-mediated diseases |
| 06/16/2005 | WO2005053720A1 Compositions for the treatment of atopic dermatitis, skin allergic conditions and acne |
| 06/16/2005 | WO2005053719A2 Compositions for the treatment of diseases of the oral cavity and upper respiratory tract |
| 06/16/2005 | WO2005053715A1 Agents for improving iron uptake |
| 06/16/2005 | WO2005053713A1 Enoxaparin for the treatment of cancer |
| 06/16/2005 | WO2005053712A1 Use of adenonsine derivatives for treating dyslipidemia, obesity, cardiovascular risk factors, metabolic syndrome, polycystic ovary syndrome, niddm |
| 06/16/2005 | WO2005053711A1 Gamma-interferon inducer |
| 06/16/2005 | WO2005053710A2 Food composition comprising glucosamine |
| 06/16/2005 | WO2005053709A2 Pharmaceutical uses of bisphosphonates |
| 06/16/2005 | WO2005053708A1 Loteprednol etabonate water base suspension formulation |
| 06/16/2005 | WO2005053707A1 Blood flow promoters for cauda equina tissues |
| 06/16/2005 | WO2005053706A1 Use of a cyclopentenone prostaglandin for delaying for the onset and/or preventing the continuation of labour |
| 06/16/2005 | WO2005053705A1 Use of a cyclopentenone prostaglandin for delaying the onset and/or preventing the continuation of labour |
| 06/16/2005 | WO2005053704A1 Method for predicting drug responsiveness in myeloid neoplasms |
| 06/16/2005 | WO2005053703A1 Combination therapy for dementia, depression and apathy |
| 06/16/2005 | WO2005053702A2 Anti-inflammatory agents |
| 06/16/2005 | WO2005053701A1 Combination of dopamine agonists and aralkyl and aralkylidene heterocyclic lactams and imides |
| 06/16/2005 | WO2005053700A1 Use of (2s,3s)2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol |
| 06/16/2005 | WO2005053699A1 Combination of a cdk inhibitor and cs-682 or a metabolite thereof |
| 06/16/2005 | WO2005053698A1 Oral formulations of desoxypeganine and uses thereof |
| 06/16/2005 | WO2005053697A2 Treatment of sexual disorders |
| 06/16/2005 | WO2005053696A1 Treatment of spondylarthropathies |
| 06/16/2005 | WO2005053695A1 Preventive or therapeutic agent for multiple sclerosis |
| 06/16/2005 | WO2005053694A1 Treatment of hpv infections and cancer |
| 06/16/2005 | WO2005053693A1 A tetrahydroquinoline derivative for treating nicotine craving |
| 06/16/2005 | WO2005053692A1 Advanced quinolinone based protein kinase inhibitors |